Search
As federal funding for cancer research has been jeopardized at NIH and academia, Parker Institute for Cancer Immunotherapy is one private institution ready to step up and broaden its impact
CSO John Connolly describes how recent new hires and a willingness to lead will expand PICI's already broad reach in cancer research...
Apr 16
SITC 2024: Parker Institute for Cancer Immunotherapy CSO John Connolly gives an overview of the latest advances in IO
He discusses the latest in TILs, cell therapy, multispecifics, oncolytic viruses and more.
Nov 9, 2024
Parker Institute for Cancer Immunotherapy's John Connolly on what he is seeing at #SITC23
John Connolly describes trends he is seeing in cell therapy, bi-specific engagers, myeloid checkpoint targets, and combinations.
Nov 4, 2023
The latest on immunotherapy with John Connolly.
Parker Institute's John Connolly provides an update on the latest in cancer immunotherapy at #JPM23.
Jan 11, 2023
.png){kind=logo}
